Literature DB >> 14610303

Follow-up of hemorheological parameters and platelet aggregation in patients with acute coronary syndromes.

Zs Marton1, B Horvath, T Alexy, G Kesmarky, Zs Gyevnar, L Czopf, T Habon, L Kovacs, E Papp, B Mezey, E Roth, I Juricskay, K Toth.   

Abstract

Pathologic hemorheological parameters and increased platelet aggregation in association with other risk factors significantly increase the possibility of the development of myocardial ischemia. Hemorheological parameters and platelet aggregation were investigated in 157 patients (mean age: 65+/-12 years) with acute coronary syndromes and in 68 healthy subjects (mean age: 36+/-6 years). Plasma fibrinogen, plasma and whole blood viscosity, red blood cell aggregation and filterability and platelet aggregation were measured in the hospital phase (after admission, on 2nd and 6th days) and monitored after discharge (at 1, 6 and 12 months). After admission all these parameters were significantly higher in patients than in control subjects (p<0.01) and almost all of them remained in the pathologic range at discharge. Some of the rheologic parameters showed a slight improvement after 1 month, but hematocrit and whole blood viscosity were higher than those after admission and of control subjects (p<0.05). After 6 and 12 months these parameters showed a small, but significant increase. Pathologically altered hemorheological parameters could be observed in patients with classical cardiovascular risk factors and significant improvement was found after elimination of them. Antiplatelet therapy was efficient in about half of the treated patients after admission; and despite a significant improvement, the proportion of ineffectively treated patients was still considerable during the follow-up. Our results support the role of abnormal hemorheological parameters in the development of myocardial ischemia and draw attention to the rheologic risk of these patients. The results of platelet aggregation measurements show the insufficiency of antiplatelet therapy at some cases and confirm the importance of guided secondary prevention.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14610303

Source DB:  PubMed          Journal:  Clin Hemorheol Microcirc        ISSN: 1386-0291            Impact factor:   2.375


  6 in total

1.  Sodium modeling attenuates rises in whole-blood viscosity during chronic hemodialysis in children with large inter-dialytic weight gain.

Authors:  Sahar A Fathallah-Shaykh; Ellen R Brooks; Craig B Langman; Kenneth R Kensey
Journal:  Pediatr Nephrol       Date:  2006-05-24       Impact factor: 3.714

2.  The role of hemorheological factors in cardiovascular medicine.

Authors:  A Toth; J Papp; M Rabai; P Kenyeres; Zs Marton; G Kesmarky; I Juricskay; H J Meiselman; K Toth
Journal:  Clin Hemorheol Microcirc       Date:  2014       Impact factor: 2.375

3.  Effects of moderate aerobic exercise training on hemorheological and laboratory parameters in ischemic heart disease patients.

Authors:  Barbara Sandor; Alexandra Nagy; Andras Toth; Miklos Rabai; Bela Mezey; Arpad Csatho; Istvan Czuriga; Kalman Toth; Eszter Szabados
Journal:  PLoS One       Date:  2014-10-27       Impact factor: 3.240

4.  Rosuvastatin Reduces Blood Viscosity in Patients with Acute Coronary Syndrome.

Authors:  Lae-Young Jung; Sang-Rok Lee; Jin-Mu Jung; Yi-Shik Kim; Sun-Hwa Lee; Kyoung-Suk Rhee; Jei-Keon Chae; Dong-Hwan Lee; Dal-Sik Kim; Won-Ho Kim; Jae-Ki Ko
Journal:  Korean Circ J       Date:  2016-03-21       Impact factor: 3.243

5.  Analysis of the Blood Viscosity Behavior in the Sicilian Study on Juvenile Myocardial Infarction.

Authors:  Gregorio Caimi; Eugenia Hopps; Maria Montana; Giuseppe Andolina; Caterina Urso; Baldassare Canino; Rosalia Lo Presti
Journal:  Clin Appl Thromb Hemost       Date:  2018-05-23       Impact factor: 2.389

6.  Dazhu Hongjingtian Preparation as Adjuvant Therapy for Unstable Angina Pectoris: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Changfeng Man; Zhe Dai; Yu Fan
Journal:  Front Pharmacol       Date:  2020-03-10       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.